



February 6, 2020

Company name: Mitsubishi Chemical Holdings Corporation
 Representative: Hitoshi Ochi
 Representative Corporate Executive Officer,
 President & Chief Executive Officer
 TSE code no.:4188, 1st section
 Contact: Shigeki Habuka
 Corporate Executive Officer, General Manager,
 Public Relations and Investor Relations Office
 Tel: [+81] (0)3-6748-7120

Notice on Revision to Consolidated Financial Results Forecast for the Fiscal Year Ending March 31, 2020

Mitsubishi Chemical Holdings Corporation has revised the forecast that it announced on November 1, 2019 for the fiscal year ending March 31, 2020, as follows.

1. Revision to consolidated financial results forecast for fiscal 2019 (April 1, 2019 – March 31, 2020)

(Billions of Yen; unless otherwise noted)

	Sales revenue	Core operating income	Operating income	Net income	Net income attributable to owners of the parent	Earnings per share (Yen)
Previous forecast (A) (announced on November 1, 2019)	3,765.0	250.0	241.0	170.0	131.0	92.26
Revised forecast (B)	3,630.0	210.0	182.0	122.0	81.0	57.04
Difference (B – A)	(135.0)	(40.0)	(59.0)	(48.0)	(50.0)	—
Difference (%)	(3.6)	(16.0)	(24.5)	(28.2)	(38.2)	—
Reference: Results for fiscal 2018	3,840.3	314.1	294.8	216.7	169.5	119.22

Notes:

- Net income before taxes: ¥221.0 billion (previous forecast); ¥159.0 billion (revised forecast)
- Core operating income is calculated as operating income (loss) excluding certain gains and expenses attributable to non-recurring factors.
- Sales revenue, core operating income, operating income, and income before taxes encompass continuing operations and exclude discontinued operations.

2. Reason for revision

Sales revenue and core operating income are expected to be lower than the previous forecast. This is because market conditions of MMA, carbon, and other Chemicals segment products will likely be poor, while it is also projected that adjustments will continue for the foreseeable future in demand for products in optical applications for displays and semiconductor and automotive applications.

In the third quarter, management expects sales revenue, net income, and net income attributable to owners of the parent to be lower than previously forecast owing to goodwill impairment charges relating to the pharmaceutical formulation materials business in the Health Care domain.

Reference:

Core operating income by segment

(Billions of Yen)

	Revised forecast	Previous forecast	Difference
Performance Products	70.0	81.0	(11.0)
Chemicals	45.0	73.0	(28.0)
Industrial Gases	89.0	93.0	(4.0)
Health Care	6.0	6.0	-
Others	-	(3.0)	3.0
Total	210.0	250.0	(40.0)

Forward-Looking Statements

The forward-looking statements are based largely on the Company's expectations and information available as of the date hereof, and are subject to risks and uncertainties which may be beyond the Company's control. Actual results could differ materially due to numerous factors, including, without limitation, market conditions, and the effect of industry competition.